nodes	percent_of_prediction	percent_of_DWPC	metapath
Atropine—Dolasetron—CYP3A4—bone cancer	0.0137	0.364	CrCbGaD
Atropine—Granisetron—CYP3A4—bone cancer	0.0125	0.333	CrCbGaD
Atropine—Cocaine—CYP3A4—bone cancer	0.00594	0.158	CrCbGaD
Atropine—Ipratropium bromide—CYP3A4—bone cancer	0.00543	0.145	CrCbGaD
Atropine—Dehydration—Cisplatin—bone cancer	0.00496	0.00579	CcSEcCtD
Atropine—Rash erythematous—Epirubicin—bone cancer	0.00493	0.00575	CcSEcCtD
Atropine—Petechiae—Methotrexate—bone cancer	0.0049	0.00572	CcSEcCtD
Atropine—Hypokalaemia—Cisplatin—bone cancer	0.00486	0.00566	CcSEcCtD
Atropine—Laryngitis—Doxorubicin—bone cancer	0.00485	0.00565	CcSEcCtD
Atropine—Feeling hot—Epirubicin—bone cancer	0.00481	0.00561	CcSEcCtD
Atropine—Ventricular arrhythmia—Doxorubicin—bone cancer	0.00472	0.0055	CcSEcCtD
Atropine—Speech disorder—Methotrexate—bone cancer	0.00469	0.00547	CcSEcCtD
Atropine—Ageusia—Epirubicin—bone cancer	0.00466	0.00543	CcSEcCtD
Atropine—Stinging—Epirubicin—bone cancer	0.00466	0.00543	CcSEcCtD
Atropine—Petechiae—Epirubicin—bone cancer	0.00459	0.00535	CcSEcCtD
Atropine—Rash erythematous—Doxorubicin—bone cancer	0.00456	0.00532	CcSEcCtD
Atropine—Blood disorder—Epirubicin—bone cancer	0.00452	0.00527	CcSEcCtD
Atropine—Feeling hot—Doxorubicin—bone cancer	0.00445	0.00519	CcSEcCtD
Atropine—Delirium—Epirubicin—bone cancer	0.00439	0.00512	CcSEcCtD
Atropine—Ageusia—Doxorubicin—bone cancer	0.00431	0.00503	CcSEcCtD
Atropine—Stinging—Doxorubicin—bone cancer	0.00431	0.00503	CcSEcCtD
Atropine—Dysarthria—Methotrexate—bone cancer	0.00426	0.00497	CcSEcCtD
Atropine—Petechiae—Doxorubicin—bone cancer	0.00425	0.00495	CcSEcCtD
Atropine—Blood disorder—Doxorubicin—bone cancer	0.00418	0.00488	CcSEcCtD
Atropine—Ventricular extrasystoles—Epirubicin—bone cancer	0.00418	0.00487	CcSEcCtD
Atropine—Respiratory failure—Methotrexate—bone cancer	0.00411	0.00479	CcSEcCtD
Atropine—Delirium—Doxorubicin—bone cancer	0.00406	0.00474	CcSEcCtD
Atropine—Acute coronary syndrome—Cisplatin—bone cancer	0.00405	0.00473	CcSEcCtD
Atropine—Myocardial infarction—Cisplatin—bone cancer	0.00403	0.0047	CcSEcCtD
Atropine—Conjunctivitis—Cisplatin—bone cancer	0.004	0.00466	CcSEcCtD
Atropine—Dysarthria—Epirubicin—bone cancer	0.00399	0.00465	CcSEcCtD
Atropine—Depressed level of consciousness—Methotrexate—bone cancer	0.00389	0.00454	CcSEcCtD
Atropine—Ventricular extrasystoles—Doxorubicin—bone cancer	0.00387	0.00451	CcSEcCtD
Atropine—Skin exfoliation—Methotrexate—bone cancer	0.00385	0.00449	CcSEcCtD
Atropine—Ventricular tachycardia—Epirubicin—bone cancer	0.00377	0.0044	CcSEcCtD
Atropine—Bradycardia—Cisplatin—bone cancer	0.00376	0.00438	CcSEcCtD
Atropine—Injection site reaction—Epirubicin—bone cancer	0.00375	0.00438	CcSEcCtD
Atropine—Dermatitis contact—Epirubicin—bone cancer	0.00373	0.00435	CcSEcCtD
Atropine—Dysarthria—Doxorubicin—bone cancer	0.00369	0.00431	CcSEcCtD
Atropine—Coma—Methotrexate—bone cancer	0.00369	0.0043	CcSEcCtD
Atropine—Skin exfoliation—Epirubicin—bone cancer	0.0036	0.0042	CcSEcCtD
Atropine—Pulmonary oedema—Methotrexate—bone cancer	0.00359	0.00419	CcSEcCtD
Atropine—Blood urea increased—Epirubicin—bone cancer	0.00356	0.00416	CcSEcCtD
Atropine—Ventricular tachycardia—Doxorubicin—bone cancer	0.00349	0.00407	CcSEcCtD
Atropine—Dry eye—Epirubicin—bone cancer	0.00349	0.00407	CcSEcCtD
Atropine—Injection site reaction—Doxorubicin—bone cancer	0.00347	0.00405	CcSEcCtD
Atropine—Dermatitis contact—Doxorubicin—bone cancer	0.00345	0.00403	CcSEcCtD
Atropine—Coma—Epirubicin—bone cancer	0.00345	0.00402	CcSEcCtD
Atropine—Rash maculo-papular—Epirubicin—bone cancer	0.00343	0.004	CcSEcCtD
Atropine—Flushing—Cisplatin—bone cancer	0.00343	0.004	CcSEcCtD
Atropine—Pulmonary oedema—Epirubicin—bone cancer	0.00336	0.00392	CcSEcCtD
Atropine—Skin exfoliation—Doxorubicin—bone cancer	0.00333	0.00389	CcSEcCtD
Atropine—Hypertonia—Epirubicin—bone cancer	0.00331	0.00386	CcSEcCtD
Atropine—Arrhythmia—Cisplatin—bone cancer	0.0033	0.00385	CcSEcCtD
Atropine—Blood urea increased—Doxorubicin—bone cancer	0.0033	0.00385	CcSEcCtD
Atropine—Dry eye—Doxorubicin—bone cancer	0.00323	0.00376	CcSEcCtD
Atropine—Erythema—Cisplatin—bone cancer	0.00321	0.00375	CcSEcCtD
Atropine—Coma—Doxorubicin—bone cancer	0.00319	0.00372	CcSEcCtD
Atropine—Rash maculo-papular—Doxorubicin—bone cancer	0.00317	0.0037	CcSEcCtD
Atropine—Pulmonary oedema—Doxorubicin—bone cancer	0.00311	0.00363	CcSEcCtD
Atropine—Hypertonia—Doxorubicin—bone cancer	0.00306	0.00357	CcSEcCtD
Atropine—Eczema—Epirubicin—bone cancer	0.00305	0.00356	CcSEcCtD
Atropine—Eye pain—Epirubicin—bone cancer	0.00303	0.00354	CcSEcCtD
Atropine—Vision blurred—Cisplatin—bone cancer	0.00303	0.00353	CcSEcCtD
Atropine—Lethargy—Methotrexate—bone cancer	0.00299	0.00348	CcSEcCtD
Atropine—Osteoarthritis—Methotrexate—bone cancer	0.00293	0.00341	CcSEcCtD
Atropine—Eczema—Doxorubicin—bone cancer	0.00282	0.00329	CcSEcCtD
Atropine—Eye pain—Doxorubicin—bone cancer	0.00281	0.00328	CcSEcCtD
Atropine—Hypoglycaemia—Epirubicin—bone cancer	0.00281	0.00327	CcSEcCtD
Atropine—Lethargy—Epirubicin—bone cancer	0.0028	0.00326	CcSEcCtD
Atropine—Irritability—Methotrexate—bone cancer	0.00279	0.00326	CcSEcCtD
Atropine—Convulsion—Cisplatin—bone cancer	0.00278	0.00325	CcSEcCtD
Atropine—Ataxia—Methotrexate—bone cancer	0.00275	0.00321	CcSEcCtD
Atropine—Hyponatraemia—Epirubicin—bone cancer	0.00275	0.00321	CcSEcCtD
Atropine—Osteoarthritis—Epirubicin—bone cancer	0.00274	0.0032	CcSEcCtD
Atropine—CHRM2—SIDS Susceptibility Pathways—FEV—bone cancer	0.00273	0.026	CbGpPWpGaD
Atropine—Anxiety—Cisplatin—bone cancer	0.00273	0.00318	CcSEcCtD
Atropine—Anaphylactic shock—Cisplatin—bone cancer	0.00262	0.00306	CcSEcCtD
Atropine—Oedema—Cisplatin—bone cancer	0.00262	0.00306	CcSEcCtD
Atropine—Cardiac arrest—Epirubicin—bone cancer	0.00261	0.00304	CcSEcCtD
Atropine—Hypoglycaemia—Doxorubicin—bone cancer	0.0026	0.00303	CcSEcCtD
Atropine—Lethargy—Doxorubicin—bone cancer	0.00259	0.00302	CcSEcCtD
Atropine—Ataxia—Epirubicin—bone cancer	0.00258	0.003	CcSEcCtD
Atropine—Tachycardia—Cisplatin—bone cancer	0.00256	0.00298	CcSEcCtD
Atropine—Dehydration—Epirubicin—bone cancer	0.00255	0.00297	CcSEcCtD
Atropine—Hyponatraemia—Doxorubicin—bone cancer	0.00255	0.00297	CcSEcCtD
Atropine—Osteoarthritis—Doxorubicin—bone cancer	0.00254	0.00296	CcSEcCtD
Atropine—Hyperhidrosis—Cisplatin—bone cancer	0.00254	0.00296	CcSEcCtD
Atropine—Dry skin—Epirubicin—bone cancer	0.00251	0.00293	CcSEcCtD
Atropine—Hypokalaemia—Epirubicin—bone cancer	0.00249	0.00291	CcSEcCtD
Atropine—Hypotension—Cisplatin—bone cancer	0.00245	0.00286	CcSEcCtD
Atropine—Cardiac arrest—Doxorubicin—bone cancer	0.00241	0.00281	CcSEcCtD
Atropine—Abdominal distension—Epirubicin—bone cancer	0.00238	0.00278	CcSEcCtD
Atropine—Ataxia—Doxorubicin—bone cancer	0.00238	0.00278	CcSEcCtD
Atropine—Dysphagia—Epirubicin—bone cancer	0.00237	0.00276	CcSEcCtD
Atropine—Dysuria—Methotrexate—bone cancer	0.00237	0.00276	CcSEcCtD
Atropine—Dehydration—Doxorubicin—bone cancer	0.00236	0.00275	CcSEcCtD
Atropine—Dyspnoea—Cisplatin—bone cancer	0.00234	0.00273	CcSEcCtD
Atropine—Erectile dysfunction—Methotrexate—bone cancer	0.00233	0.00272	CcSEcCtD
Atropine—Dry skin—Doxorubicin—bone cancer	0.00232	0.00271	CcSEcCtD
Atropine—Hypokalaemia—Doxorubicin—bone cancer	0.00231	0.00269	CcSEcCtD
Atropine—Angina pectoris—Epirubicin—bone cancer	0.00231	0.00269	CcSEcCtD
Atropine—Drowsiness—Methotrexate—bone cancer	0.00226	0.00263	CcSEcCtD
Atropine—Depression—Methotrexate—bone cancer	0.00225	0.00262	CcSEcCtD
Atropine—Pain—Cisplatin—bone cancer	0.00224	0.00262	CcSEcCtD
Atropine—Dysuria—Epirubicin—bone cancer	0.00221	0.00258	CcSEcCtD
Atropine—Abdominal distension—Doxorubicin—bone cancer	0.00221	0.00257	CcSEcCtD
Atropine—Conjunctivitis—Methotrexate—bone cancer	0.00219	0.00256	CcSEcCtD
Atropine—Dysphagia—Doxorubicin—bone cancer	0.00219	0.00256	CcSEcCtD
Atropine—Sweating—Methotrexate—bone cancer	0.00216	0.00252	CcSEcCtD
Atropine—Feeling abnormal—Cisplatin—bone cancer	0.00216	0.00252	CcSEcCtD
Atropine—Hyperglycaemia—Epirubicin—bone cancer	0.00214	0.00249	CcSEcCtD
Atropine—Angina pectoris—Doxorubicin—bone cancer	0.00213	0.00249	CcSEcCtD
Atropine—Drowsiness—Epirubicin—bone cancer	0.00211	0.00246	CcSEcCtD
Atropine—Body temperature increased—Cisplatin—bone cancer	0.00207	0.00242	CcSEcCtD
Atropine—Conjunctivitis—Epirubicin—bone cancer	0.00205	0.00239	CcSEcCtD
Atropine—Dysuria—Doxorubicin—bone cancer	0.00205	0.00239	CcSEcCtD
Atropine—Sweating—Epirubicin—bone cancer	0.00202	0.00236	CcSEcCtD
Atropine—Hyperglycaemia—Doxorubicin—bone cancer	0.00198	0.00231	CcSEcCtD
Atropine—Drowsiness—Doxorubicin—bone cancer	0.00195	0.00228	CcSEcCtD
Atropine—Hypersensitivity—Cisplatin—bone cancer	0.00193	0.00225	CcSEcCtD
Atropine—Bradycardia—Epirubicin—bone cancer	0.00193	0.00225	CcSEcCtD
Atropine—Conjunctivitis—Doxorubicin—bone cancer	0.0019	0.00221	CcSEcCtD
Atropine—Asthenia—Cisplatin—bone cancer	0.00188	0.00219	CcSEcCtD
Atropine—Sweating—Doxorubicin—bone cancer	0.00187	0.00218	CcSEcCtD
Atropine—Diarrhoea—Cisplatin—bone cancer	0.00179	0.00209	CcSEcCtD
Atropine—Bradycardia—Doxorubicin—bone cancer	0.00179	0.00208	CcSEcCtD
Atropine—Mental disorder—Methotrexate—bone cancer	0.00177	0.00207	CcSEcCtD
Atropine—Erythema—Methotrexate—bone cancer	0.00176	0.00206	CcSEcCtD
Atropine—Flushing—Epirubicin—bone cancer	0.00176	0.00205	CcSEcCtD
Atropine—Dysgeusia—Methotrexate—bone cancer	0.00173	0.00201	CcSEcCtD
Atropine—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00171	0.0163	CbGpPWpGaD
Atropine—Arrhythmia—Epirubicin—bone cancer	0.00169	0.00197	CcSEcCtD
Atropine—Vomiting—Cisplatin—bone cancer	0.00167	0.00194	CcSEcCtD
Atropine—Vision blurred—Methotrexate—bone cancer	0.00166	0.00194	CcSEcCtD
Atropine—CHRM4—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	0.00166	0.0158	CbGpPWpGaD
Atropine—Mental disorder—Epirubicin—bone cancer	0.00166	0.00194	CcSEcCtD
Atropine—Rash—Cisplatin—bone cancer	0.00165	0.00193	CcSEcCtD
Atropine—Dermatitis—Cisplatin—bone cancer	0.00165	0.00193	CcSEcCtD
Atropine—Erythema—Epirubicin—bone cancer	0.00165	0.00192	CcSEcCtD
Atropine—Flushing—Doxorubicin—bone cancer	0.00163	0.0019	CcSEcCtD
Atropine—Tension—Epirubicin—bone cancer	0.00162	0.00189	CcSEcCtD
Atropine—Dysgeusia—Epirubicin—bone cancer	0.00162	0.00188	CcSEcCtD
Atropine—Nervousness—Epirubicin—bone cancer	0.0016	0.00187	CcSEcCtD
Atropine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.0016	0.0152	CbGpPWpGaD
Atropine—CHRM5—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	0.00159	0.0151	CbGpPWpGaD
Atropine—Vertigo—Methotrexate—bone cancer	0.00158	0.00185	CcSEcCtD
Atropine—Arrhythmia—Doxorubicin—bone cancer	0.00157	0.00183	CcSEcCtD
Atropine—Nausea—Cisplatin—bone cancer	0.00156	0.00182	CcSEcCtD
Atropine—Vision blurred—Epirubicin—bone cancer	0.00156	0.00181	CcSEcCtD
Atropine—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.00155	0.0148	CbGpPWpGaD
Atropine—Mental disorder—Doxorubicin—bone cancer	0.00154	0.00179	CcSEcCtD
Atropine—Convulsion—Methotrexate—bone cancer	0.00153	0.00178	CcSEcCtD
Atropine—Erythema—Doxorubicin—bone cancer	0.00153	0.00178	CcSEcCtD
Atropine—Agitation—Epirubicin—bone cancer	0.00152	0.00177	CcSEcCtD
Atropine—Chest pain—Methotrexate—bone cancer	0.0015	0.00175	CcSEcCtD
Atropine—Tension—Doxorubicin—bone cancer	0.0015	0.00175	CcSEcCtD
Atropine—Dysgeusia—Doxorubicin—bone cancer	0.0015	0.00174	CcSEcCtD
Atropine—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.00149	0.0142	CbGpPWpGaD
Atropine—Nervousness—Doxorubicin—bone cancer	0.00148	0.00173	CcSEcCtD
Atropine—Vertigo—Epirubicin—bone cancer	0.00148	0.00173	CcSEcCtD
Atropine—Syncope—Epirubicin—bone cancer	0.00148	0.00173	CcSEcCtD
Atropine—Palpitations—Epirubicin—bone cancer	0.00146	0.0017	CcSEcCtD
Atropine—CHRM1—Circadian rythm related genes—TNFRSF11A—bone cancer	0.00145	0.0138	CbGpPWpGaD
Atropine—Confusional state—Methotrexate—bone cancer	0.00145	0.00169	CcSEcCtD
Atropine—Loss of consciousness—Epirubicin—bone cancer	0.00145	0.00169	CcSEcCtD
Atropine—Anaphylactic shock—Methotrexate—bone cancer	0.00144	0.00168	CcSEcCtD
Atropine—Vision blurred—Doxorubicin—bone cancer	0.00144	0.00168	CcSEcCtD
Atropine—CHRM3—GPCRs, Other—GRM1—bone cancer	0.00144	0.0137	CbGpPWpGaD
Atropine—Convulsion—Epirubicin—bone cancer	0.00143	0.00167	CcSEcCtD
Atropine—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.00143	0.0136	CbGpPWpGaD
Atropine—CHRM2—GPCRs, Other—GRM1—bone cancer	0.00142	0.0135	CbGpPWpGaD
Atropine—Chest pain—Epirubicin—bone cancer	0.0014	0.00164	CcSEcCtD
Atropine—Agitation—Doxorubicin—bone cancer	0.0014	0.00164	CcSEcCtD
Atropine—Anxiety—Epirubicin—bone cancer	0.0014	0.00163	CcSEcCtD
Atropine—Hyperhidrosis—Methotrexate—bone cancer	0.00139	0.00162	CcSEcCtD
Atropine—Dry mouth—Epirubicin—bone cancer	0.00137	0.0016	CcSEcCtD
Atropine—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.00137	0.0131	CbGpPWpGaD
Atropine—Vertigo—Doxorubicin—bone cancer	0.00137	0.0016	CcSEcCtD
Atropine—Syncope—Doxorubicin—bone cancer	0.00137	0.0016	CcSEcCtD
Atropine—Confusional state—Epirubicin—bone cancer	0.00136	0.00158	CcSEcCtD
Atropine—Palpitations—Doxorubicin—bone cancer	0.00135	0.00157	CcSEcCtD
Atropine—Anaphylactic shock—Epirubicin—bone cancer	0.00135	0.00157	CcSEcCtD
Atropine—Oedema—Epirubicin—bone cancer	0.00135	0.00157	CcSEcCtD
Atropine—Hypotension—Methotrexate—bone cancer	0.00134	0.00157	CcSEcCtD
Atropine—Loss of consciousness—Doxorubicin—bone cancer	0.00134	0.00156	CcSEcCtD
Atropine—Shock—Epirubicin—bone cancer	0.00132	0.00155	CcSEcCtD
Atropine—Convulsion—Doxorubicin—bone cancer	0.00132	0.00154	CcSEcCtD
Atropine—Tachycardia—Epirubicin—bone cancer	0.00131	0.00153	CcSEcCtD
Atropine—Hyperhidrosis—Epirubicin—bone cancer	0.0013	0.00152	CcSEcCtD
Atropine—Insomnia—Methotrexate—bone cancer	0.0013	0.00152	CcSEcCtD
Atropine—Chest pain—Doxorubicin—bone cancer	0.0013	0.00152	CcSEcCtD
Atropine—Anxiety—Doxorubicin—bone cancer	0.0013	0.00151	CcSEcCtD
Atropine—Dyspnoea—Methotrexate—bone cancer	0.00128	0.0015	CcSEcCtD
Atropine—Somnolence—Methotrexate—bone cancer	0.00128	0.00149	CcSEcCtD
Atropine—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.00127	0.0121	CbGpPWpGaD
Atropine—Dry mouth—Doxorubicin—bone cancer	0.00127	0.00148	CcSEcCtD
Atropine—Dyspepsia—Methotrexate—bone cancer	0.00127	0.00148	CcSEcCtD
Atropine—Hypotension—Epirubicin—bone cancer	0.00126	0.00147	CcSEcCtD
Atropine—Confusional state—Doxorubicin—bone cancer	0.00126	0.00147	CcSEcCtD
Atropine—Anaphylactic shock—Doxorubicin—bone cancer	0.00125	0.00145	CcSEcCtD
Atropine—Oedema—Doxorubicin—bone cancer	0.00125	0.00145	CcSEcCtD
Atropine—Fatigue—Methotrexate—bone cancer	0.00124	0.00145	CcSEcCtD
Atropine—Pain—Methotrexate—bone cancer	0.00123	0.00144	CcSEcCtD
Atropine—Shock—Doxorubicin—bone cancer	0.00123	0.00143	CcSEcCtD
Atropine—Insomnia—Epirubicin—bone cancer	0.00122	0.00142	CcSEcCtD
Atropine—Tachycardia—Doxorubicin—bone cancer	0.00122	0.00142	CcSEcCtD
Atropine—Hyperhidrosis—Doxorubicin—bone cancer	0.0012	0.0014	CcSEcCtD
Atropine—Dyspnoea—Epirubicin—bone cancer	0.0012	0.0014	CcSEcCtD
Atropine—Somnolence—Epirubicin—bone cancer	0.0012	0.0014	CcSEcCtD
Atropine—Feeling abnormal—Methotrexate—bone cancer	0.00119	0.00138	CcSEcCtD
Atropine—Dyspepsia—Epirubicin—bone cancer	0.00119	0.00138	CcSEcCtD
Atropine—Gastrointestinal pain—Methotrexate—bone cancer	0.00118	0.00137	CcSEcCtD
Atropine—Hypotension—Doxorubicin—bone cancer	0.00116	0.00136	CcSEcCtD
Atropine—Fatigue—Epirubicin—bone cancer	0.00116	0.00135	CcSEcCtD
Atropine—CHRM4—G alpha (i) signalling events—RGS1—bone cancer	0.00115	0.011	CbGpPWpGaD
Atropine—CHRM4—G alpha (i) signalling events—GRM4—bone cancer	0.00115	0.011	CbGpPWpGaD
Atropine—Pain—Epirubicin—bone cancer	0.00115	0.00134	CcSEcCtD
Atropine—Constipation—Epirubicin—bone cancer	0.00115	0.00134	CcSEcCtD
Atropine—CHRM5—G alpha (q) signalling events—GRM1—bone cancer	0.00115	0.0109	CbGpPWpGaD
Atropine—Urticaria—Methotrexate—bone cancer	0.00114	0.00133	CcSEcCtD
Atropine—Body temperature increased—Methotrexate—bone cancer	0.00114	0.00133	CcSEcCtD
Atropine—Abdominal pain—Methotrexate—bone cancer	0.00114	0.00133	CcSEcCtD
Atropine—Insomnia—Doxorubicin—bone cancer	0.00113	0.00131	CcSEcCtD
Atropine—CHRM1—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	0.00112	0.0107	CbGpPWpGaD
Atropine—CHRM3—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	0.00112	0.0106	CbGpPWpGaD
Atropine—Dyspnoea—Doxorubicin—bone cancer	0.00111	0.0013	CcSEcCtD
Atropine—Feeling abnormal—Epirubicin—bone cancer	0.00111	0.00129	CcSEcCtD
Atropine—Somnolence—Doxorubicin—bone cancer	0.00111	0.00129	CcSEcCtD
Atropine—CHRM2—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	0.00111	0.0105	CbGpPWpGaD
Atropine—Gastrointestinal pain—Epirubicin—bone cancer	0.0011	0.00128	CcSEcCtD
Atropine—Dyspepsia—Doxorubicin—bone cancer	0.0011	0.00128	CcSEcCtD
Atropine—Fatigue—Doxorubicin—bone cancer	0.00107	0.00125	CcSEcCtD
Atropine—Urticaria—Epirubicin—bone cancer	0.00107	0.00125	CcSEcCtD
Atropine—Pain—Doxorubicin—bone cancer	0.00107	0.00124	CcSEcCtD
Atropine—Constipation—Doxorubicin—bone cancer	0.00107	0.00124	CcSEcCtD
Atropine—Body temperature increased—Epirubicin—bone cancer	0.00106	0.00124	CcSEcCtD
Atropine—Abdominal pain—Epirubicin—bone cancer	0.00106	0.00124	CcSEcCtD
Atropine—Hypersensitivity—Methotrexate—bone cancer	0.00106	0.00124	CcSEcCtD
Atropine—CHRM3—Regulation of insulin secretion—GNA11—bone cancer	0.00106	0.0101	CbGpPWpGaD
Atropine—Asthenia—Methotrexate—bone cancer	0.00103	0.0012	CcSEcCtD
Atropine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.00103	0.00979	CbGpPWpGaD
Atropine—Feeling abnormal—Doxorubicin—bone cancer	0.00103	0.0012	CcSEcCtD
Atropine—Gastrointestinal pain—Doxorubicin—bone cancer	0.00102	0.00119	CcSEcCtD
Atropine—Pruritus—Methotrexate—bone cancer	0.00102	0.00119	CcSEcCtD
Atropine—CHRM3—GPCRs, Other—SMO—bone cancer	0.00101	0.00963	CbGpPWpGaD
Atropine—CHRM2—GPCRs, Other—SMO—bone cancer	0.001	0.00954	CbGpPWpGaD
Atropine—Hypersensitivity—Epirubicin—bone cancer	0.000992	0.00116	CcSEcCtD
Atropine—Urticaria—Doxorubicin—bone cancer	0.00099	0.00115	CcSEcCtD
Atropine—Abdominal pain—Doxorubicin—bone cancer	0.000985	0.00115	CcSEcCtD
Atropine—Body temperature increased—Doxorubicin—bone cancer	0.000985	0.00115	CcSEcCtD
Atropine—Diarrhoea—Methotrexate—bone cancer	0.000985	0.00115	CcSEcCtD
Atropine—Asthenia—Epirubicin—bone cancer	0.000966	0.00113	CcSEcCtD
Atropine—Pruritus—Epirubicin—bone cancer	0.000953	0.00111	CcSEcCtD
Atropine—Dizziness—Methotrexate—bone cancer	0.000952	0.00111	CcSEcCtD
Atropine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000934	0.00889	CbGpPWpGaD
Atropine—CHRM4—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000928	0.00883	CbGpPWpGaD
Atropine—Diarrhoea—Epirubicin—bone cancer	0.000921	0.00107	CcSEcCtD
Atropine—Hypersensitivity—Doxorubicin—bone cancer	0.000918	0.00107	CcSEcCtD
Atropine—Vomiting—Methotrexate—bone cancer	0.000915	0.00107	CcSEcCtD
Atropine—Rash—Methotrexate—bone cancer	0.000907	0.00106	CcSEcCtD
Atropine—Dermatitis—Methotrexate—bone cancer	0.000906	0.00106	CcSEcCtD
Atropine—Headache—Methotrexate—bone cancer	0.000901	0.00105	CcSEcCtD
Atropine—Asthenia—Doxorubicin—bone cancer	0.000894	0.00104	CcSEcCtD
Atropine—Dizziness—Epirubicin—bone cancer	0.00089	0.00104	CcSEcCtD
Atropine—CHRM5—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000889	0.00846	CbGpPWpGaD
Atropine—Pruritus—Doxorubicin—bone cancer	0.000882	0.00103	CcSEcCtD
Atropine—Vomiting—Epirubicin—bone cancer	0.000856	0.000999	CcSEcCtD
Atropine—Nausea—Methotrexate—bone cancer	0.000855	0.000997	CcSEcCtD
Atropine—Diarrhoea—Doxorubicin—bone cancer	0.000853	0.000994	CcSEcCtD
Atropine—Rash—Epirubicin—bone cancer	0.000849	0.00099	CcSEcCtD
Atropine—Dermatitis—Epirubicin—bone cancer	0.000848	0.000989	CcSEcCtD
Atropine—Headache—Epirubicin—bone cancer	0.000844	0.000984	CcSEcCtD
Atropine—CHRM3—Integration of energy metabolism—GNA11—bone cancer	0.000832	0.00792	CbGpPWpGaD
Atropine—Dizziness—Doxorubicin—bone cancer	0.000824	0.000961	CcSEcCtD
Atropine—CHRM1—G alpha (q) signalling events—GRM1—bone cancer	0.00081	0.00771	CbGpPWpGaD
Atropine—CHRM3—G alpha (q) signalling events—GRM1—bone cancer	0.000807	0.00768	CbGpPWpGaD
Atropine—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000805	0.00767	CbGpPWpGaD
Atropine—Nausea—Epirubicin—bone cancer	0.0008	0.000933	CcSEcCtD
Atropine—Vomiting—Doxorubicin—bone cancer	0.000792	0.000924	CcSEcCtD
Atropine—Rash—Doxorubicin—bone cancer	0.000786	0.000916	CcSEcCtD
Atropine—Dermatitis—Doxorubicin—bone cancer	0.000785	0.000915	CcSEcCtD
Atropine—Headache—Doxorubicin—bone cancer	0.000781	0.00091	CcSEcCtD
Atropine—CHRM2—G alpha (i) signalling events—RGS1—bone cancer	0.000768	0.00731	CbGpPWpGaD
Atropine—CHRM2—G alpha (i) signalling events—GRM4—bone cancer	0.000768	0.00731	CbGpPWpGaD
Atropine—CHRM5—G alpha (q) signalling events—GNA11—bone cancer	0.000741	0.00705	CbGpPWpGaD
Atropine—Nausea—Doxorubicin—bone cancer	0.00074	0.000863	CcSEcCtD
Atropine—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000733	0.00698	CbGpPWpGaD
Atropine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.000724	0.00689	CbGpPWpGaD
Atropine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.000722	0.00687	CbGpPWpGaD
Atropine—CHRM4—GPCR ligand binding—GRM4—bone cancer	0.000698	0.00665	CbGpPWpGaD
Atropine—CHRM5—GPCR ligand binding—GRM4—bone cancer	0.000669	0.00637	CbGpPWpGaD
Atropine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.000663	0.00631	CbGpPWpGaD
Atropine—CHRM1—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000626	0.00596	CbGpPWpGaD
Atropine—CHRM3—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000624	0.00594	CbGpPWpGaD
Atropine—CHRM2—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000618	0.00588	CbGpPWpGaD
Atropine—CHRM4—GPCR ligand binding—GRM1—bone cancer	0.000606	0.00576	CbGpPWpGaD
Atropine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000593	0.00564	CbGpPWpGaD
Atropine—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000585	0.00557	CbGpPWpGaD
Atropine—CHRM5—GPCR ligand binding—GRM1—bone cancer	0.00058	0.00552	CbGpPWpGaD
Atropine—CHRM1—G alpha (q) signalling events—GNA11—bone cancer	0.000522	0.00497	CbGpPWpGaD
Atropine—CHRM3—G alpha (q) signalling events—GNA11—bone cancer	0.00052	0.00495	CbGpPWpGaD
Atropine—CHRM1—Circadian rythm related genes—GNA11—bone cancer	0.000492	0.00469	CbGpPWpGaD
Atropine—CHRM1—Circadian rythm related genes—EZH2—bone cancer	0.00049	0.00467	CbGpPWpGaD
Atropine—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000481	0.00458	CbGpPWpGaD
Atropine—CHRM1—GPCR ligand binding—GRM4—bone cancer	0.000471	0.00448	CbGpPWpGaD
Atropine—CHRM3—GPCR ligand binding—GRM4—bone cancer	0.000469	0.00447	CbGpPWpGaD
Atropine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.000467	0.00444	CbGpPWpGaD
Atropine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.000465	0.00443	CbGpPWpGaD
Atropine—CHRM2—GPCR ligand binding—GRM4—bone cancer	0.000465	0.00443	CbGpPWpGaD
Atropine—CHRM4—Regulation of Actin Cytoskeleton—BRAF—bone cancer	0.000461	0.00439	CbGpPWpGaD
Atropine—CHRM5—Regulation of Actin Cytoskeleton—BRAF—bone cancer	0.000442	0.00421	CbGpPWpGaD
Atropine—CHRM4—GPCR ligand binding—SMO—bone cancer	0.000427	0.00406	CbGpPWpGaD
Atropine—CHRM5—GPCR ligand binding—SMO—bone cancer	0.000409	0.00389	CbGpPWpGaD
Atropine—CHRM1—GPCR ligand binding—GRM1—bone cancer	0.000408	0.00389	CbGpPWpGaD
Atropine—CHRM3—GPCR ligand binding—GRM1—bone cancer	0.000407	0.00387	CbGpPWpGaD
Atropine—CHRM2—GPCR ligand binding—GRM1—bone cancer	0.000403	0.00384	CbGpPWpGaD
Atropine—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000395	0.00376	CbGpPWpGaD
Atropine—CHRM4—GPCR downstream signaling—RGS1—bone cancer	0.000395	0.00376	CbGpPWpGaD
Atropine—CHRM4—GPCR downstream signaling—GRM4—bone cancer	0.000395	0.00376	CbGpPWpGaD
Atropine—CHRM5—GPCR downstream signaling—GRM4—bone cancer	0.000378	0.0036	CbGpPWpGaD
Atropine—CHRM5—GPCR downstream signaling—RGS1—bone cancer	0.000378	0.0036	CbGpPWpGaD
Atropine—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.000373	0.00355	CbGpPWpGaD
Atropine—CHRM4—Signaling by GPCR—GRM4—bone cancer	0.000358	0.00341	CbGpPWpGaD
Atropine—CHRM4—Signaling by GPCR—RGS1—bone cancer	0.000358	0.00341	CbGpPWpGaD
Atropine—CHRM5—Signaling by GPCR—GRM4—bone cancer	0.000343	0.00327	CbGpPWpGaD
Atropine—CHRM5—Signaling by GPCR—RGS1—bone cancer	0.000343	0.00327	CbGpPWpGaD
Atropine—CHRM4—GPCR downstream signaling—GRM1—bone cancer	0.000342	0.00326	CbGpPWpGaD
Atropine—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	0.000337	0.00321	CbGpPWpGaD
Atropine—CHRM5—GPCR downstream signaling—GRM1—bone cancer	0.000328	0.00312	CbGpPWpGaD
Atropine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000325	0.00309	CbGpPWpGaD
Atropine—CHRM1—Regulation of Actin Cytoskeleton—BRAF—bone cancer	0.000311	0.00296	CbGpPWpGaD
Atropine—CHRM4—Signaling by GPCR—GRM1—bone cancer	0.000311	0.00296	CbGpPWpGaD
Atropine—CHRM3—Regulation of Actin Cytoskeleton—BRAF—bone cancer	0.00031	0.00295	CbGpPWpGaD
Atropine—CHRM2—Regulation of Actin Cytoskeleton—BRAF—bone cancer	0.000307	0.00292	CbGpPWpGaD
Atropine—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	0.000304	0.00289	CbGpPWpGaD
Atropine—CHRM3—Metabolism—NDUFA12—bone cancer	0.000302	0.00288	CbGpPWpGaD
Atropine—CHRM5—Signaling by GPCR—GRM1—bone cancer	0.000298	0.00283	CbGpPWpGaD
Atropine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000293	0.00279	CbGpPWpGaD
Atropine—CHRM1—GPCR ligand binding—SMO—bone cancer	0.000288	0.00274	CbGpPWpGaD
Atropine—CHRM3—GPCR ligand binding—SMO—bone cancer	0.000287	0.00273	CbGpPWpGaD
Atropine—CHRM2—GPCR ligand binding—SMO—bone cancer	0.000284	0.0027	CbGpPWpGaD
Atropine—CHRM1—Circadian rythm related genes—CDK4—bone cancer	0.000277	0.00263	CbGpPWpGaD
Atropine—CHRM1—GPCR downstream signaling—RGS1—bone cancer	0.000266	0.00253	CbGpPWpGaD
Atropine—CHRM1—GPCR downstream signaling—GRM4—bone cancer	0.000266	0.00253	CbGpPWpGaD
Atropine—CHRM3—GPCR downstream signaling—RGS1—bone cancer	0.000265	0.00253	CbGpPWpGaD
Atropine—CHRM3—GPCR downstream signaling—GRM4—bone cancer	0.000265	0.00253	CbGpPWpGaD
Atropine—CHRM4—Regulation of Actin Cytoskeleton—EGFR—bone cancer	0.000264	0.00252	CbGpPWpGaD
Atropine—CHRM2—GPCR downstream signaling—RGS1—bone cancer	0.000263	0.0025	CbGpPWpGaD
Atropine—CHRM2—GPCR downstream signaling—GRM4—bone cancer	0.000263	0.0025	CbGpPWpGaD
Atropine—CYP1A2—Biological oxidations—CYP3A4—bone cancer	0.000255	0.00243	CbGpPWpGaD
Atropine—CHRM5—Regulation of Actin Cytoskeleton—EGFR—bone cancer	0.000253	0.00241	CbGpPWpGaD
Atropine—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	0.000252	0.0024	CbGpPWpGaD
Atropine—CHRM3—Metabolism—NT5C3A—bone cancer	0.00025	0.00238	CbGpPWpGaD
Atropine—CHRM1—Signaling by GPCR—RGS1—bone cancer	0.000242	0.0023	CbGpPWpGaD
Atropine—CHRM1—Signaling by GPCR—GRM4—bone cancer	0.000242	0.0023	CbGpPWpGaD
Atropine—CHRM3—Signaling by GPCR—GRM4—bone cancer	0.000241	0.00229	CbGpPWpGaD
Atropine—CHRM3—Signaling by GPCR—RGS1—bone cancer	0.000241	0.00229	CbGpPWpGaD
Atropine—CHRM2—Signaling by GPCR—GRM4—bone cancer	0.000239	0.00227	CbGpPWpGaD
Atropine—CHRM2—Signaling by GPCR—RGS1—bone cancer	0.000239	0.00227	CbGpPWpGaD
Atropine—CHRM1—GPCR downstream signaling—GRM1—bone cancer	0.000231	0.0022	CbGpPWpGaD
Atropine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.00023	0.00219	CbGpPWpGaD
Atropine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.00023	0.00219	CbGpPWpGaD
Atropine—CHRM3—GPCR downstream signaling—GRM1—bone cancer	0.00023	0.00219	CbGpPWpGaD
Atropine—CHRM2—GPCR downstream signaling—GRM1—bone cancer	0.000228	0.00217	CbGpPWpGaD
Atropine—CHRM4—GPCR downstream signaling—GNA11—bone cancer	0.000221	0.0021	CbGpPWpGaD
Atropine—CHRM4—Signaling by GPCR—SMO—bone cancer	0.000219	0.00208	CbGpPWpGaD
Atropine—CYP1A2—Biological oxidations—GSTP1—bone cancer	0.000218	0.00208	CbGpPWpGaD
Atropine—CHRM2—SIDS Susceptibility Pathways—JUN—bone cancer	0.000216	0.00205	CbGpPWpGaD
Atropine—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	0.000215	0.00205	CbGpPWpGaD
Atropine—CHRM4—Signaling Pathways—RGS1—bone cancer	0.000212	0.00202	CbGpPWpGaD
Atropine—CHRM4—Signaling Pathways—GRM4—bone cancer	0.000212	0.00202	CbGpPWpGaD
Atropine—CHRM5—GPCR downstream signaling—GNA11—bone cancer	0.000211	0.00201	CbGpPWpGaD
Atropine—CHRM5—Signaling by GPCR—SMO—bone cancer	0.00021	0.002	CbGpPWpGaD
Atropine—CHRM1—Signaling by GPCR—GRM1—bone cancer	0.00021	0.00199	CbGpPWpGaD
Atropine—CHRM3—Signaling by GPCR—GRM1—bone cancer	0.000209	0.00199	CbGpPWpGaD
Atropine—CHRM2—Signaling by GPCR—GRM1—bone cancer	0.000207	0.00197	CbGpPWpGaD
Atropine—CHRM5—Signaling Pathways—RGS1—bone cancer	0.000203	0.00193	CbGpPWpGaD
Atropine—CHRM5—Signaling Pathways—GRM4—bone cancer	0.000203	0.00193	CbGpPWpGaD
Atropine—CHRM4—Signaling by GPCR—GNA11—bone cancer	0.0002	0.00191	CbGpPWpGaD
Atropine—CHRM4—GPCR downstream signaling—IL3—bone cancer	0.0002	0.0019	CbGpPWpGaD
Atropine—CHRM5—Signaling by GPCR—GNA11—bone cancer	0.000192	0.00183	CbGpPWpGaD
Atropine—CHRM5—GPCR downstream signaling—IL3—bone cancer	0.000191	0.00182	CbGpPWpGaD
Atropine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000189	0.0018	CbGpPWpGaD
Atropine—CHRM4—Signaling Pathways—GRM1—bone cancer	0.000184	0.00175	CbGpPWpGaD
Atropine—CHRM4—Signaling by GPCR—IL3—bone cancer	0.000182	0.00173	CbGpPWpGaD
Atropine—CHRM1—Circadian rythm related genes—JUN—bone cancer	0.000178	0.0017	CbGpPWpGaD
Atropine—CHRM1—Regulation of Actin Cytoskeleton—EGFR—bone cancer	0.000178	0.0017	CbGpPWpGaD
Atropine—CHRM3—Regulation of Actin Cytoskeleton—EGFR—bone cancer	0.000178	0.00169	CbGpPWpGaD
Atropine—CHRM2—Regulation of Actin Cytoskeleton—EGFR—bone cancer	0.000176	0.00167	CbGpPWpGaD
Atropine—CHRM5—Signaling Pathways—GRM1—bone cancer	0.000176	0.00167	CbGpPWpGaD
Atropine—CHRM5—Signaling by GPCR—IL3—bone cancer	0.000174	0.00166	CbGpPWpGaD
Atropine—CYP1A2—Metabolism—NDUFA12—bone cancer	0.000153	0.00146	CbGpPWpGaD
Atropine—CHRM1—GPCR downstream signaling—GNA11—bone cancer	0.000149	0.00142	CbGpPWpGaD
Atropine—CHRM3—GPCR downstream signaling—GNA11—bone cancer	0.000148	0.00141	CbGpPWpGaD
Atropine—CHRM1—Signaling by GPCR—SMO—bone cancer	0.000148	0.00141	CbGpPWpGaD
Atropine—CHRM3—Signaling by GPCR—SMO—bone cancer	0.000147	0.0014	CbGpPWpGaD
Atropine—CHRM2—GPCR downstream signaling—GNA11—bone cancer	0.000147	0.0014	CbGpPWpGaD
Atropine—CHRM2—Signaling by GPCR—SMO—bone cancer	0.000146	0.00139	CbGpPWpGaD
Atropine—CHRM1—Signaling Pathways—GRM4—bone cancer	0.000143	0.00136	CbGpPWpGaD
Atropine—CHRM1—Signaling Pathways—RGS1—bone cancer	0.000143	0.00136	CbGpPWpGaD
Atropine—CHRM3—Signaling Pathways—RGS1—bone cancer	0.000142	0.00135	CbGpPWpGaD
Atropine—CHRM3—Signaling Pathways—GRM4—bone cancer	0.000142	0.00135	CbGpPWpGaD
Atropine—CHRM2—Signaling Pathways—RGS1—bone cancer	0.000141	0.00134	CbGpPWpGaD
Atropine—CHRM2—Signaling Pathways—GRM4—bone cancer	0.000141	0.00134	CbGpPWpGaD
Atropine—CHRM1—Signaling by GPCR—GNA11—bone cancer	0.000135	0.00129	CbGpPWpGaD
Atropine—CHRM1—GPCR downstream signaling—IL3—bone cancer	0.000135	0.00128	CbGpPWpGaD
Atropine—CHRM3—Signaling by GPCR—GNA11—bone cancer	0.000135	0.00128	CbGpPWpGaD
Atropine—CHRM3—GPCR downstream signaling—IL3—bone cancer	0.000134	0.00128	CbGpPWpGaD
Atropine—CHRM2—Signaling by GPCR—GNA11—bone cancer	0.000133	0.00127	CbGpPWpGaD
Atropine—CHRM2—GPCR downstream signaling—IL3—bone cancer	0.000133	0.00127	CbGpPWpGaD
Atropine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000133	0.00126	CbGpPWpGaD
Atropine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000132	0.00126	CbGpPWpGaD
Atropine—CHRM4—Signaling Pathways—SMO—bone cancer	0.000129	0.00123	CbGpPWpGaD
Atropine—CYP1A2—Metabolism—NT5C3A—bone cancer	0.000127	0.00121	CbGpPWpGaD
Atropine—CHRM5—Signaling Pathways—SMO—bone cancer	0.000124	0.00118	CbGpPWpGaD
Atropine—CHRM1—Signaling Pathways—GRM1—bone cancer	0.000124	0.00118	CbGpPWpGaD
Atropine—CHRM3—Signaling Pathways—GRM1—bone cancer	0.000123	0.00117	CbGpPWpGaD
Atropine—CHRM1—Signaling by GPCR—IL3—bone cancer	0.000122	0.00117	CbGpPWpGaD
Atropine—CHRM2—Signaling Pathways—GRM1—bone cancer	0.000122	0.00116	CbGpPWpGaD
Atropine—CHRM3—Signaling by GPCR—IL3—bone cancer	0.000122	0.00116	CbGpPWpGaD
Atropine—CHRM2—Signaling by GPCR—IL3—bone cancer	0.000121	0.00115	CbGpPWpGaD
Atropine—CHRM4—Signaling Pathways—GNA11—bone cancer	0.000118	0.00113	CbGpPWpGaD
Atropine—CHRM1—Circadian rythm related genes—TP53—bone cancer	0.000118	0.00112	CbGpPWpGaD
Atropine—CHRM5—Signaling Pathways—GNA11—bone cancer	0.000113	0.00108	CbGpPWpGaD
Atropine—CHRM4—Signaling Pathways—ATF1—bone cancer	0.00011	0.00105	CbGpPWpGaD
Atropine—CHRM3—Metabolism—ENO2—bone cancer	0.00011	0.00104	CbGpPWpGaD
Atropine—CHRM4—Signaling Pathways—IL3—bone cancer	0.000107	0.00102	CbGpPWpGaD
Atropine—CHRM5—Signaling Pathways—ATF1—bone cancer	0.000105	0.001	CbGpPWpGaD
Atropine—CHRM5—Signaling Pathways—IL3—bone cancer	0.000103	0.000978	CbGpPWpGaD
Atropine—CHRM3—Metabolism—DHFR—bone cancer	0.000102	0.000969	CbGpPWpGaD
Atropine—CHRM3—Metabolism—GNA11—bone cancer	9.51e-05	0.000905	CbGpPWpGaD
Atropine—CHRM4—Signaling Pathways—TGFBR2—bone cancer	9.17e-05	0.000873	CbGpPWpGaD
Atropine—CHRM5—Signaling Pathways—TGFBR2—bone cancer	8.78e-05	0.000836	CbGpPWpGaD
Atropine—CHRM1—Signaling Pathways—SMO—bone cancer	8.72e-05	0.00083	CbGpPWpGaD
Atropine—CHRM3—Signaling Pathways—SMO—bone cancer	8.69e-05	0.000828	CbGpPWpGaD
Atropine—CHRM4—Signaling Pathways—IGF1R—bone cancer	8.63e-05	0.000822	CbGpPWpGaD
Atropine—CHRM3—Metabolism—CYP3A4—bone cancer	8.62e-05	0.000821	CbGpPWpGaD
Atropine—CHRM2—Signaling Pathways—SMO—bone cancer	8.61e-05	0.00082	CbGpPWpGaD
Atropine—CHRM5—Signaling Pathways—IGF1R—bone cancer	8.26e-05	0.000787	CbGpPWpGaD
Atropine—CHRM1—Signaling Pathways—GNA11—bone cancer	7.98e-05	0.000759	CbGpPWpGaD
Atropine—CHRM3—Signaling Pathways—GNA11—bone cancer	7.95e-05	0.000757	CbGpPWpGaD
Atropine—CHRM2—Signaling Pathways—GNA11—bone cancer	7.87e-05	0.00075	CbGpPWpGaD
Atropine—CHRM1—Signaling Pathways—ATF1—bone cancer	7.42e-05	0.000706	CbGpPWpGaD
Atropine—CHRM3—Signaling Pathways—ATF1—bone cancer	7.39e-05	0.000704	CbGpPWpGaD
Atropine—CHRM3—Metabolism—GSTP1—bone cancer	7.37e-05	0.000702	CbGpPWpGaD
Atropine—CHRM2—Signaling Pathways—ATF1—bone cancer	7.32e-05	0.000697	CbGpPWpGaD
Atropine—CHRM1—Signaling Pathways—IL3—bone cancer	7.23e-05	0.000688	CbGpPWpGaD
Atropine—CHRM3—Signaling Pathways—IL3—bone cancer	7.21e-05	0.000686	CbGpPWpGaD
Atropine—CHRM2—Signaling Pathways—IL3—bone cancer	7.14e-05	0.00068	CbGpPWpGaD
Atropine—CHRM4—Signaling Pathways—KIT—bone cancer	6.26e-05	0.000596	CbGpPWpGaD
Atropine—CHRM1—Signaling Pathways—TGFBR2—bone cancer	6.18e-05	0.000589	CbGpPWpGaD
Atropine—CHRM3—Signaling Pathways—TGFBR2—bone cancer	6.17e-05	0.000587	CbGpPWpGaD
Atropine—CHRM2—Signaling Pathways—TGFBR2—bone cancer	6.11e-05	0.000581	CbGpPWpGaD
Atropine—CHRM5—Signaling Pathways—KIT—bone cancer	5.99e-05	0.000571	CbGpPWpGaD
Atropine—CHRM4—Signaling Pathways—BRAF—bone cancer	5.88e-05	0.00056	CbGpPWpGaD
Atropine—CHRM1—Signaling Pathways—IGF1R—bone cancer	5.82e-05	0.000554	CbGpPWpGaD
Atropine—CHRM3—Signaling Pathways—IGF1R—bone cancer	5.8e-05	0.000552	CbGpPWpGaD
Atropine—CHRM2—Signaling Pathways—IGF1R—bone cancer	5.74e-05	0.000547	CbGpPWpGaD
Atropine—CHRM4—Signaling by GPCR—EGFR—bone cancer	5.7e-05	0.000543	CbGpPWpGaD
Atropine—CHRM5—Signaling Pathways—BRAF—bone cancer	5.63e-05	0.000536	CbGpPWpGaD
Atropine—CYP1A2—Metabolism—ENO2—bone cancer	5.56e-05	0.000529	CbGpPWpGaD
Atropine—CHRM5—Signaling by GPCR—EGFR—bone cancer	5.46e-05	0.00052	CbGpPWpGaD
Atropine—CYP1A2—Metabolism—DHFR—bone cancer	5.15e-05	0.000491	CbGpPWpGaD
Atropine—CHRM4—Signaling Pathways—MDM2—bone cancer	4.93e-05	0.000469	CbGpPWpGaD
Atropine—CYP1A2—Metabolism—GNA11—bone cancer	4.82e-05	0.000459	CbGpPWpGaD
Atropine—CHRM5—Signaling Pathways—MDM2—bone cancer	4.72e-05	0.000449	CbGpPWpGaD
Atropine—CYP1A2—Metabolism—CYP3A4—bone cancer	4.37e-05	0.000416	CbGpPWpGaD
Atropine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.34e-05	0.000414	CbGpPWpGaD
Atropine—CHRM4—Signaling Pathways—JUN—bone cancer	4.28e-05	0.000408	CbGpPWpGaD
Atropine—CHRM1—Signaling Pathways—KIT—bone cancer	4.22e-05	0.000402	CbGpPWpGaD
Atropine—CHRM3—Signaling Pathways—KIT—bone cancer	4.21e-05	0.0004	CbGpPWpGaD
Atropine—CHRM4—Signaling Pathways—MMP9—bone cancer	4.17e-05	0.000397	CbGpPWpGaD
Atropine—CHRM2—Signaling Pathways—KIT—bone cancer	4.17e-05	0.000397	CbGpPWpGaD
Atropine—CHRM5—Signaling Pathways—JUN—bone cancer	4.1e-05	0.000391	CbGpPWpGaD
Atropine—CHRM5—Signaling Pathways—MMP9—bone cancer	3.99e-05	0.00038	CbGpPWpGaD
Atropine—CHRM1—Signaling Pathways—BRAF—bone cancer	3.97e-05	0.000378	CbGpPWpGaD
Atropine—CHRM3—Signaling Pathways—BRAF—bone cancer	3.95e-05	0.000376	CbGpPWpGaD
Atropine—CHRM2—Signaling Pathways—BRAF—bone cancer	3.92e-05	0.000373	CbGpPWpGaD
Atropine—CHRM1—Signaling by GPCR—EGFR—bone cancer	3.84e-05	0.000366	CbGpPWpGaD
Atropine—CHRM3—Signaling by GPCR—EGFR—bone cancer	3.83e-05	0.000365	CbGpPWpGaD
Atropine—CHRM3—Metabolism—PTGS2—bone cancer	3.82e-05	0.000364	CbGpPWpGaD
Atropine—CHRM2—Signaling by GPCR—EGFR—bone cancer	3.8e-05	0.000361	CbGpPWpGaD
Atropine—CYP1A2—Metabolism—GSTP1—bone cancer	3.73e-05	0.000356	CbGpPWpGaD
Atropine—CHRM4—Signaling Pathways—EGFR—bone cancer	3.37e-05	0.000321	CbGpPWpGaD
Atropine—CHRM1—Signaling Pathways—MDM2—bone cancer	3.32e-05	0.000316	CbGpPWpGaD
Atropine—CHRM3—Signaling Pathways—MDM2—bone cancer	3.31e-05	0.000315	CbGpPWpGaD
Atropine—CHRM2—Signaling Pathways—MDM2—bone cancer	3.28e-05	0.000312	CbGpPWpGaD
Atropine—CHRM5—Signaling Pathways—EGFR—bone cancer	3.23e-05	0.000307	CbGpPWpGaD
Atropine—CHRM1—Signaling Pathways—JUN—bone cancer	2.89e-05	0.000275	CbGpPWpGaD
Atropine—CHRM3—Signaling Pathways—JUN—bone cancer	2.88e-05	0.000274	CbGpPWpGaD
Atropine—CHRM2—Signaling Pathways—JUN—bone cancer	2.85e-05	0.000271	CbGpPWpGaD
Atropine—CHRM4—Signaling Pathways—TP53—bone cancer	2.83e-05	0.000269	CbGpPWpGaD
Atropine—CHRM1—Signaling Pathways—MMP9—bone cancer	2.81e-05	0.000268	CbGpPWpGaD
Atropine—CHRM3—Signaling Pathways—MMP9—bone cancer	2.8e-05	0.000267	CbGpPWpGaD
Atropine—CHRM2—Signaling Pathways—MMP9—bone cancer	2.77e-05	0.000264	CbGpPWpGaD
Atropine—CHRM5—Signaling Pathways—TP53—bone cancer	2.71e-05	0.000258	CbGpPWpGaD
Atropine—CHRM1—Signaling Pathways—EGFR—bone cancer	2.27e-05	0.000216	CbGpPWpGaD
Atropine—CHRM3—Signaling Pathways—EGFR—bone cancer	2.26e-05	0.000216	CbGpPWpGaD
Atropine—CHRM2—Signaling Pathways—EGFR—bone cancer	2.24e-05	0.000213	CbGpPWpGaD
Atropine—CYP1A2—Metabolism—PTGS2—bone cancer	1.93e-05	0.000184	CbGpPWpGaD
Atropine—CHRM1—Signaling Pathways—TP53—bone cancer	1.91e-05	0.000182	CbGpPWpGaD
Atropine—CHRM3—Signaling Pathways—TP53—bone cancer	1.9e-05	0.000181	CbGpPWpGaD
Atropine—CHRM2—Signaling Pathways—TP53—bone cancer	1.88e-05	0.000179	CbGpPWpGaD
